Hologic, Inc. (HOLX) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,126,234 shares of the medical equipment provider’s stock after selling 20,026 shares during the period. Bank of New York Mellon Corp owned about 0.78% of Hologic worth $84,518,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. WINTON GROUP Ltd bought a new position in Hologic in the second quarter worth approximately $5,837,000. Andra AP fonden bought a new position in Hologic in the second quarter worth approximately $3,581,000. Amussen Hunsaker Associates LLC bought a new position in Hologic in the second quarter worth approximately $159,000. Jane Street Group LLC raised its stake in Hologic by 595.7% in the second quarter. Jane Street Group LLC now owns 48,029 shares of the medical equipment provider’s stock worth $1,909,000 after buying an additional 41,125 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its stake in Hologic by 247.3% in the second quarter. Advisors Asset Management Inc. now owns 48,763 shares of the medical equipment provider’s stock worth $528,000 after buying an additional 34,724 shares in the last quarter. 98.74% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. Needham & Company LLC boosted their price objective on shares of Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Wednesday, August 1st. Deutsche Bank boosted their price objective on shares of Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a research note on Wednesday, August 1st. Canaccord Genuity reissued a “hold” rating and issued a $43.00 price objective on shares of Hologic in a research note on Thursday. Finally, Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. Hologic currently has an average rating of “Hold” and a consensus target price of $44.41.

NASDAQ HOLX opened at $41.78 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. Hologic, Inc. has a 12-month low of $35.10 and a 12-month high of $45.09. The firm has a market capitalization of $11.23 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.88 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). Hologic had a positive return on equity of 22.93% and a negative net margin of 3.46%. The firm had revenue of $813.50 million during the quarter, compared to analysts’ expectations of $808.63 million. During the same period in the prior year, the firm posted $0.50 earnings per share. Hologic’s revenue for the quarter was up 1.3% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 2.4 EPS for the current year.

In other news, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the sale, the director now directly owns 66,006 shares of the company’s stock, valued at $2,686,444.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Karleen Marie Oberton sold 1,312 shares of the business’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $41.90, for a total transaction of $54,972.80. Following the sale, the chief financial officer now directly owns 10,206 shares in the company, valued at $427,631.40. The disclosure for this sale can be found here. Insiders have sold 49,519 shares of company stock worth $2,003,965 over the last three months. Corporate insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hologic, Inc. (HOLX) Shares Sold by Bank of New York Mellon Corp” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.wkrb13.com/2018/11/11/hologic-inc-holx-shares-sold-by-bank-of-new-york-mellon-corp.html.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Cost of Capital Explained

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply